Q-omics provides the consensus-scored CHST12 profile across patient tissues and cancer cell-line models. CHST12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, CHST12 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, CHST12 RNA expression shows 19,230 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, HNSC, and ACC as cancer lineages where CHST12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CHST12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CHST12 survival associations across molecular data types. CHST12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CHST12 RNA expression–survival associations across cancer types. High CHST12 expression shows unfavorable associations in KICH, LIHC, COAD, UVM and OV, but favorable associations in PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for CHST12 RNA expression.
This table summarizes CHST12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CHST12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CHST12 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, KIRP and COAD. The HNSC box plot shows higher CHST12 RNA expression in tumor versus normal tissue (log2 FC = +0.890, t-test p < 0.001).
This table shows molecular features associated with CHST12 in patient tissues and cancer cell lines. In patient samples, CHST12 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CHST12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and LARGE_INTESTINE.
